Constantine Moschonas

Constantine has been involved in patient-focused clinical research for over three decades. He has played a major role in defining new approaches for ARDS (acute respiratory distress syndrome) and in the ground-breaking study evaluating critical asymptomatic carotid artery stenosis (ACAS Trial) and its treatment. He was also involved in the multiple sclerosis trials that lead to the first-ever effective treatment of relapsing MS.
In 2015, in collaboration with Dr. Ron Korn, Constantine helped develop a proprietary model for studying the effects of stroke and recovery. He captained the largest enrolling site for Lilly’s Daybreak Alzheimer’s clinical trial that demonstrated that amyloid was probably not destructing in Alzheimer’s disease but may be playing a protective role.
Throughout his career, Constantine has remained involved in teaching. He is presently Chairman of the neurology section of the Internal Medicine Residency program at HonorHealth. He continues to collaborate on various patient-centered clinical projects with researchers around the world.